Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma

  • Technology appraisal guidance
  • TA178
  • Published: 
Download guidance (PDF)

Appendix B: Sources of evidence considered by the Committee

A. The assessment report for this appraisal was prepared by Peninsula Technology Assessment Group, University of Exeter.

  • Thompson Coon J, Hoyle M, Green C et al., Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma, May 2008.

B. The following organisations accepted the invitation to participate in this appraisal. They were invited to comment on the draft scope, assessment report and the appraisal consultation document (ACD). Organisations listed in I and II were also invited to make written submissions and have the opportunity to appeal against the final appraisal determination.

I) Manufacturer/sponsor:

  • Bayer (sorafenib)

  • Pfizer (sunitinib)

  • Roche Products (bevacizumab)

  • Wyeth Pharmaceuticals (temsirolimus)

II) Professional/specialist and patient/carer groups:

  • British Uro-oncology Group

  • Cancer Network Pharmacists Forum

  • Cancer Research UK

  • Cancerbackup

  • James Whale Fund for Kidney Cancer

  • Kidney Cancer UK

  • Kidney Research UK

  • National Kidney Federation

  • Rarer Cancers Forum

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians, Medical Oncology Joint Special Committee

  • South Asian Health Foundation

III) Other consultees

  • Cambridgeshire Primary Care Trust

  • Department of Health

  • Welsh Assembly Government

IV) Commentator organisations (did not provide written evidence and without the right of appeal)

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • MRC Clinical Trials Unit

  • National Collaborating Centre for Cancer

  • National Coordinating Centre for Health Technology Assessment

  • NHS Quality Improvement Scotland

  • Novartis Pharmaceuticals (interleukin-2)

  • Peninsula Technology Assessment Group, University of Exeter

  • Roche Products (interferon alfa)

C. The following individuals were selected from clinical specialist and patient advocate nominations from the non-manufacturer/sponsor consultees and commentators. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on bevacizumab, sorafenib, sunitinib and temsirolimus by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr David Chao, Consultant Medical Oncologist nominated by Royal College of Physicians – clinical specialist

  • Dr Pat Hanlon, nominated by Kidney Cancer UK – patient expert

  • Mr Bill Savage, nominated by the Rarer Cancers Forum – patient expert